NCT05765877

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer : a Single-arm, Exploratory Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Pingping Song · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).

Conditions

• Non-Small Cell Lung Cancer(NSCLC)

Interventions

Type	Name	Description
DRUG	WX-0593 Tablets	60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.

Timeline

• Start date: 2023-03-01
• Primary completion: 2027-03-01
• Completion: 2029-03-01
• First posted: 2023-03-13
• Last updated: 2025-06-12

Locations

1 site across 1 country: China